U.S., March 5 -- ClinicalTrials.gov registry received information related to the study (NCT06856837) titled '- IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases' on Feb. 18.
Brief Summary: This is a prospective, randomized, open-label, multicenter phase II investigating the therapy of Fruquintinib in combination with Tislelizumab in patients with MSS/pMMR metastatic colorectal cancer without liver metastases.
Study Start Date: April 01
Study Type: INTERVENTIONAL
Condition:
Metastatic Colorectal Cancer
Intervention:
DRUG: Fruquintinib
highly selective and potent oral inhibitor of vascu...